Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies
Abbott Laboratories has agreed to pay $670 million to settle a major lawsuit and other claims alleging its premature infant formula causes necrotizing enterocolitis (NEC). The settlement follows
Baxter hires new CFO with visa contingency
Baxter International has named John Rogers, formerly CFO of Smith+Nephew and WPP, as its new CFO, with his start date of October 1 contingent on him securing the necessary U.S. visa and work permits. If the visa isn't obtained by then, he will temporarily work from the company's U.K. offices. This appointment comes as Baxter is undergoing restructuring initiatives, including divesting its Kidney Care businesses, and aims to stabilize the business and strengthen its balance sheet.
Baxter International (BAX) Taps John Rogers As Chief Financial Officer
Baxter International (NYSE:BAX) has appointed John Rogers as its new Chief Financial Officer, a move expected to support the company's ongoing operational transformation, portfolio cleanup, and balance sheet efforts. Rogers' background in corporate restructuring aligns with Baxter's goals of cost reductions and removing stranded costs by 2027. Investors will be watching how Rogers addresses debt and operating cash flow after his transition date of October 1, 2026.
Baxter hires CFO from Smith & Nephew
Baxter has appointed John Rogers, formerly CFO of Smith & Nephew, as its new executive vice president and CFO, effective October 1. Rogers is tasked with advancing Baxter's multiyear restructuring and turnaround strategy, bringing experience in leading transformations in slow-growth industries. His appointment follows Baxter's recent sales of its biopharma solutions and Vantive kidney care businesses.
1,435,460 Shares in Baxter International Inc. $BAX Acquired by Tocqueville Asset Management L.P.
Tocqueville Asset Management L.P. recently acquired 1,435,460 shares of Baxter International Inc. (NYSE:BAX) valued at approximately $30.6 million, representing 0.28% of the company. Institutional investors and hedge funds collectively own 90.19% of BAX. Analysts generally maintain a "Hold" rating for the stock, with an average price target of $22.45, despite Baxter exceeding its recent quarterly earnings expectations.
Great Lakes Advisors LLC Purchases New Holdings in Baxter International Inc. $BAX
Great Lakes Advisors LLC has acquired a new position in Baxter International Inc. (NYSE:BAX), purchasing 237,106 shares valued at approximately $5.055 million during the second quarter. Other institutional investors have also adjusted their holdings in the company, with Baxter International's stock recently opening at $26.61 and the company announcing a quarterly dividend of $0.01 per share. Analysts generally rate the stock as "Hold" with a consensus target price of $22.45.
BlackRock Inc. Makes New $1.74 Billion Investment in Baxter International Inc. $BAX
BlackRock Inc. has acquired a significant new position in Baxter International Inc. (NYSE:BAX), purchasing over 81 million shares valued at approximately $1.74 billion, representing about 15.83% of the company. This investment comes as Baxter reported stronger-than-expected quarterly earnings and revenue, while maintaining its fiscal 2026 EPS guidance. Despite a cautious "Hold" consensus rating from analysts, institutional investors now collectively own 90.19% of Baxter's stock, and the company recently declared a quarterly dividend.
Smith+Nephew CFO joins Baxter
John Rogers, the CFO of Smith+Nephew, is stepping down to take on the role of EVP and CFO at Baxter, effective in October. This move follows Smith+Nephew's recent reduction in its annual growth forecast and comes as the company navigates its RISE strategy, which aims for significant revenue growth and free cash flow by 2028. Pierre Palassian will serve as interim CFO for Smith+Nephew while a successor for Rogers is sought.
Baxter finds its replacement finance chief, reaffirms outlook
Baxter International has named its new Chief Financial Officer, John Rogers. The company also reaffirmed its financial outlook. This announcement was made on August 19, 2026, by Crain's Chicago Business.
GE HealthCare names new CFO
GE HealthCare has appointed William Grogan as its new CFO, filling the vacancy left by Jay Saccaro. Grogan, formerly CFO at Xylem, is set to join GE HealthCare on September 14, 2026. Analysts from Stifel and RBC Capital Markets have welcomed the appointment, citing Grogan's strong track record in meeting earnings expectations, expanding margins, and simplifying operating systems, despite his lack of specific medtech experience.
Cardinal Health (CAH) Taps Anita Zielinski As Chief Accounting Officer
Cardinal Health (NYSE: CAH) has appointed Anita Zielinski as Chief Accounting Officer, bringing extensive financial and operational experience from her previous roles, including interim CFO at Baxter. This strategic hire aligns with Cardinal Health's ongoing transformation efforts, enhancing financial oversight and accountability, especially given the company's significant annual sales and active buyback program. Zielinski's expertise is expected to strengthen financial controls and execution amidst challenges like high debt and product recall exposure.
Cardinal Health (CAH) Taps Anita Zielinski As Chief Accounting Officer
Cardinal Health (NYSE: CAH) has appointed Anita Zielinski as Chief Accounting Officer, bringing extensive financial and operational experience from her previous roles at Baxter, Sysco, and Ernst & Young. This strategic hire aims to strengthen financial oversight amidst Cardinal Health's ongoing transformation efforts and addresses concerns such as high debt and product recall exposure. Zielinski's appointment is expected to enhance the company's financial function, focusing on automation and specialty growth.
Baxter Appoints Smith+Nephew CFO John Rogers as Chief Financial Officer
Baxter International Inc. has appointed John Rogers, current CFO of Smith+Nephew, as its new executive vice president and chief financial officer, effective October 1, 2026. Rogers brings extensive experience in finance leadership and large-scale corporate transformations across the medical technology, advertising, and retail sectors. His appointment is expected to support Baxter's efforts to stabilize operations, strengthen its balance sheet, and improve overall financial performance.
Baxter appoints John Rogers as CFO; Andrew Hider interim CFO
Baxter has announced the appointment of John Rogers as Executive Vice President and Chief Financial Officer, effective October 1, 2026. Andrew Hider will serve as interim CFO from September 15, 2026, until Rogers takes over, with Bernie Heine appointed as interim Chief Accounting Officer & Controller. This organizational change follows the upcoming departure of interim CFO Anita Zielinski.
Baxter Appoints John Rogers Chief Financial Officer
Baxter International Inc. announced the appointment of John Rogers as executive vice president and chief financial officer (CFO), effective October 1, 2026. Rogers, a global medtech CFO with extensive experience at companies like Smith+Nephew and WPP plc, will report to CEO Andrew Hider and play a key role in advancing Baxter's turnaround and financial discipline. The company also reiterated its full-year 2026 financial outlook.
Baxter International Names John Rogers Chief Financial Officer
Baxter International has appointed John Rogers as its new Chief Financial Officer. This announcement follows closely after several other recent developments for the company, including pricing its upsized cash tender offers and amending its five-year credit agreement. The company has also seen recent analyst rating adjustments and updates on other executive roles.
Form 8K BAXTER INTERNATIONAL INC For: 19 August By Investing.com
This article from Investing.com announces the filing of a Form 8K by BAXTER INTERNATIONAL INC for August 19. It provides a brief financial update on the company's stock performance. The article appears to be a notice of a regulatory filing rather than an in-depth analysis.
Equity Investment Corp Makes New Investment in Baxter International Inc. $BAX
Equity Investment Corp significantly increased its stake in Baxter International Inc. (NYSE:BAX) during the second quarter, purchasing over 6.8 million shares valued at approximately $146.8 million. This investment makes Baxter International the ninth-largest holding in Equity Investment Corp's portfolio, representing 2.8% of its total. The article also details recent financial performance, analyst ratings, and dividend information for Baxter International, noting the company's recent earnings beat and a declared quarterly dividend.
Baxter International (BAX) Amends Credit Agreement and Upsizes D
Baxter International (BAX) has amended its credit agreement, modifying the net leverage ratio covenant for increased financial flexibility. Concurrently, the company upsized its debt tender offers to $600 million, aiming to repurchase four series of senior notes, reflecting a proactive approach to managing its capital structure and debt obligations. This strategic financial management allows Baxter to optimize its debt profile and balance sheet efficiently.
Baxter International Revises Credit Agreement and Increases Tender Offer Limit to $600 Million
Baxter International Inc. has announced an amendment to its five-year credit agreement, revising the net leverage ratio covenant and removing Baxter World Trade SRL as a borrower. Additionally, the company has increased the aggregate purchase price cap for its cash tender offers from $500 million to $600 million, targeting specific senior notes, and confirmed no further tenders will be accepted after August 17, 2026. These financial adjustments aim to optimize the company's capital structure.
Baxter Amends Five-Year Credit Agreement, Raises Leverage Limit and Removes World Trade Borrower
Baxter International Inc. (BAX) has amended its five-year credit agreement to increase the maximum net leverage ratio for five fiscal quarters through September 30, 2027. The amendment also removes Baxter World Trade SRL as a borrower. This change, led by JPMorgan Chase Bank, aims to provide Baxter with enhanced financial flexibility and simplify its borrower group.
COO Stock Surges 22% in Past Three Months: What's Driving the Uptrend?
The Cooper Companies (COO) stock has surged 22.2% in the past three months, driven by strong contact lens demand, recovery in fertility markets, and consistent market share gains. Despite competition and some regional weakness, the company's innovative product portfolio and strategic review of CooperSurgical position it for continued growth. Zacks Investment Research currently rates COO as a "Buy" due to its attractive long-term growth profile.
COO Stock Surges 22% in Past Three Months: What's Driving the Uptrend?
The Cooper Companies (COO) stock has surged 22.2% in the past three months, driven by strong contact lens demand, recovery in fertility markets, and strategic portfolio optimization. The company reported record revenues and increased EPS, maintaining market share leadership in CooperVision and experiencing growth in CooperSurgical. While facing competition and Asia-Pacific market challenges, its underlying growth profile and potential for strategic changes in CooperSurgical make it an attractive long-term investment.
Baxter’s interim CFO leaves for Cardinal Health
Anita Zielinski, Baxter's interim CFO, will be leaving the company to join Cardinal Health as its new chief accounting officer. Zielinski, who joined Baxter in February 2025 and became interim CFO in March 2026, will start her new role at Cardinal Health on November 5, 2026, and will receive a significant sign-on bonus and restricted share units. Baxter has not yet named a new CFO following this departure and recent other leadership changes.
Pzena Investment Management LLC Takes $1.39 Billion Position in Baxter International Inc. $BAX
Pzena Investment Management LLC has acquired a significant stake in Baxter International Inc. (NYSE:BAX), purchasing 65.3 million shares valued at approximately $1.39 billion, making it their third-largest holding. Despite this large investment, analyst sentiment for BAX remains cautious, with a majority rating it as "Hold" and an average price target of $22.45. Baxter International recently surpassed its quarterly earnings and revenue expectations and has provided positive fiscal year 2026 EPS guidance.
Baxter Bros Inc. Makes New Investment in Thermo Fisher Scientific Inc. $TMO
Baxter Bros Inc. has acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by purchasing 18,827 shares valued at approximately $9.44 million, making it their 26th largest position. Thermo Fisher Scientific recently reported strong quarterly earnings, beating analyst estimates with EPS of $6.03 and a 10.5% revenue increase, while reaffirming its fiscal 2026 EPS guidance. Despite insider selling, analysts maintain a "Moderate Buy" rating for TMO with an average price target of $619.41.
Baxter International Inc. stock underperforms Monday when compared to competitors
Baxter International Inc. (BAX) shares fell 3.07% on Monday, underperforming the broader stock market, which also experienced declines. The S&P 500 Index dropped 0.52% and the Dow Jones Industrial Average fell 0.51%. This marked the second consecutive day of losses for Baxter International stock.
Baxter’s Interim CFO Anita Zielinski Departs for Cardinal Health
Anita Zielinski, Baxter’s interim chief financial officer, is resigning on September 15 to become the chief accounting officer at Cardinal Health. She will receive a $750,000 signing bonus and $1 million in restricted stock units from Cardinal Health to compensate for forfeited earnings from her previous role. This move follows Baxter's recent Q2 earnings report, which showed $2.96 billion in sales, a 5% increase year-over-year.
Baxter’s interim CFO is leaving for Cardinal Health
Anita Zielinski, Baxter's interim CFO, is departing in September to become the chief accounting officer and SVP of finance at Cardinal Health, effective November 5. Zielinski's move comes after less than two years at Baxter, where she also served as SVP, chief accounting officer, and controller. Baxter recently reported strong Q2 results and increased its full-year outlook, but has not yet announced Zielinski's successor.
AMG National Trust Bank Invests $2.52 Million in Baxter International Inc. $BAX
AMG National Trust Bank has initiated a new position in Baxter International Inc. (NYSE:BAX) by investing approximately $2.52 million in the second quarter. Other institutional investors like Bank of New York Mellon Corp and GAMMA Investing LLC have also made significant moves in Baxter stock. The article also details recent analyst rating changes, Baxter's financial performance, and an upcoming dividend announcement.
Janney Montgomery Scott LLC Lowers Stake in Stryker Corporation $SYK
Janney Montgomery Scott LLC has reduced its stake in Stryker Corporation (NYSE:SYK) by 17.6% in the second quarter, selling 17,151 shares and retaining 80,254 shares valued at $25.3 million. Despite this, Stryker reported strong financial results, with quarterly EPS of $3.69 exceeding estimates and revenue increasing by 9.4% year-over-year. The company also declared a quarterly dividend of $0.88 per share and maintains a "Moderate Buy" consensus rating from analysts.
Citi Sticks to Their Buy Rating for Irhythm Technologies (IRTC)
Citi has reiterated a Buy rating for Irhythm Technologies (IRTC) with a price target of $157.00. This comes despite a GAAP net loss for the company in its latest quarter, though revenue increased. Analyst consensus on the stock remains a Strong Buy, but insider sentiment is negative due to recent share sales.
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
Faeth Therapeutics (Nasdaq: FTH) has expanded its executive team with the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations. These strategic hires aim to bolster the company's technical operations, particularly in CMC and supply chain, and enhance investor engagement as Faeth advances its PIKTOR clinical programs for cancer treatment.
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
West Pharmaceutical Services (WST) stock has seen a significant rally, surging 38.1% since the end of March, driven by strong organic revenue growth and increased adjusted EPS. The company benefits from high demand for its proprietary products, particularly those used in biologics, biosimilars, and GLP-1 therapies, alongside improvements in manufacturing productivity and compliance upgrades. Despite potential near-term execution risks and competitive pressures, WST maintains a favorable growth outlook.
Baxter International Inc. stock underperforms Friday when compared to competitors
Baxter International Inc. (BAX) stock fell 1.18% to $26.73 on Friday, underperforming the broader market. The S&P 500 Index declined 0.17% and the Dow Jones Industrial Average fell 0.20% on the same day. The company's shares closed 10.90% below their 52-week high of $30.00, reached on July 30th.
Baxter International interim CFO Anita Zielinski to resign in September
Baxter International Inc. announced that its interim CFO, Anita Zielinski, will resign effective September 15, 2026, to join another organization. The company stated that her departure is not due to any disagreements with management or financial disclosures.
Form 8K BAXTER INTERNATIONAL INC For: 14 August By Investing.com
This article announces the filing of a Form 8K by Baxter International Inc. on August 14. The content is a brief notification from Investing.com about this financial disclosure. It primarily serves as an alert for investors interested in Baxter International Inc.'s latest regulatory filings.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Omnicell (OMCL) has increased its 2026 earnings outlook after a strong second quarter, partially boosted by a one-time tariff refund. The company faces a $6 million headwind from rising memory-chip costs but plans to offset this with operational discipline and cost control. Despite a "Strong Sell" Zacks Rank, the stock shows favorable growth, value, and momentum characteristics.
Nuwellis (NASDAQ: NUWE) boosts revenue, flags going concern and Nasdaq risks
Nuwellis (NASDAQ: NUWE) reported increased revenue for the quarter and first half of 2026, driven by strong console and circuit sales, and also improved its gross margin. Despite these revenue gains and bolstered liquidity from recent equity financings, the company still faces significant financial challenges including substantial net losses, an accumulated deficit of $325.7 million, and unresolved material weaknesses in internal controls. The company has taken steps to comply with Nasdaq's minimum equity requirements through warrant reclassification and exercise but remains under monitoring for delisting risk.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Omnicell (OMCL) has raised its 2026 earnings outlook after a strong second quarter, though a significant portion of the profit improvement came from a one-time tariff refund. The company faces increased memory-chip costs expected to impact gross margins but plans to leverage cost control and operating efficiency to absorb these pressures. Omnicell's updated guidance also includes widened product bookings and a reduction in annual recurring revenue expectations due to slower development of certain opportunities and lengthy hospital approval cycles.
Baxter International (NYSE:BAX) Raised to "Hold" at Zacks Research
Zacks Research upgraded Baxter International (NYSE:BAX) from "strong sell" to "hold," aligning with the broader analyst consensus. This upgrade follows the company's strong quarterly performance, where it exceeded EPS and revenue expectations. Institutional investors hold a significant portion of the stock, which saw a 2.4% decline on Tuesday, opening at $26.95.
Baxter International Inc. stock underperforms Wednesday when compared to competitors
Baxter International Inc. (BAX) stock fell 2.39% to $26.95 on Wednesday, underperforming the broader market. This marked the second consecutive day of losses for the company, even as the S&P 500 Index rose 0.26% and the Dow Jones Industrial Average slightly declined by 0.04%.
Axogen (AXGN) Is Up 5.4% After Raising 2026 Revenue Outlook Despite Ongoing Losses – Has The Bull Case Changed?
Axogen (AXGN) saw its stock rise by 5.4% after reporting Q2 2026 sales of US$69.73 million and a net loss of US$1.52 million, alongside raising its full-year 2026 revenue outlook to at least US$279 million. This increased guidance signals management's confidence in demand for its nerve repair portfolio despite ongoing losses, while the company continues to invest heavily in capacity and commercialization. The article explores how this updated outlook impacts Axogen's investment narrative, noting its dependence on a single biologic portfolio and the potential influence of regulatory and reimbursement pressures.
Richard Pzena Buys LKQ Corp (LKQ) -- Shares Look 38% Undervalued on GF Value
Richard Pzena's firm significantly increased its stake in LKQ Corp (LKQ), purchasing over 9 million shares at $26.33, bringing total holdings to 15.4 million shares. This move suggests Pzena sees LKQ as a value opportunity, especially after a 17.68% year-to-date decline, classifying the stock as "Significantly Undervalued" with a GF Value of $40.00 against a current price of $24.72. The investment aligns with Pzena's strategy of targeting good businesses temporarily priced at a discount, betting on a cyclical recovery for LKQ despite some short-term financial pressures.
Deepa Abi Joins Baxter International as Vice President, Global Business Solutions
Deepa Abi has been appointed as Vice President, Global Business Solutions at Baxter International Inc., bringing over 25 years of global leadership experience in healthcare, consumer goods, technology, and consulting. In her new role, she will lead the company's Global Business Solutions function, focusing on operational excellence, digital transformation, and enterprise-wide business transformation initiatives. Her appointment is expected to bolster Baxter's commitment to innovation and continuous improvement in its global operations.
Baxter International interim CFO Anita Zielinski to resign in September
Baxter International announced that interim CFO Anita Zielinski will resign effective September 15, 2026, to join another organization. The company stated her resignation was not due to any disagreements with management or the board regarding operations, policies, financial disclosures, or accounting matters. This information was disclosed in an SEC filing on July 31, 2026.
Form 8K BAXTER INTERNATIONAL INC For: 11 August By Investing.com
Investing.com reported the filing of a Form 8K by Baxter International Inc. on August 11. The article provides the title of the filing and indicates it pertains to Baxter International, a company whose stock is tracked on financial markets.
Baxter International interim CFO Anita Zielinski to resign in September
Baxter International Inc. announced that Anita Zielinski, interim CFO, will resign effective September 15, 2026, to join another organization. The company stated her resignation is not due to any disagreements with management or the board. This information was disclosed in an SEC filing on July 31, 2026.
Baxter International Inc. (NYSE:BAX) Given Average Recommendation of "Reduce" by Analysts
Thirteen research firms have given Baxter International Inc. (NYSE:BAX) an average rating of "Reduce," with a collective price target of $22.45, below its current trading price of $27.84. Despite this cautious outlook, Baxter International reported strong quarterly results, exceeding analyst expectations with an adjusted EPS of $0.56 and revenue of $2.96 billion. Institutional investors hold a significant 90.19% stake in the company, with major firms like BlackRock and Pzena Investment Management recently increasing their positions.
Baxter International (NYSE:BAX) Stock Crosses Above 200-Day Moving Average - Here's Why
Baxter International (NYSE:BAX) stock recently crossed above its 200-day moving average, trading at $27.84, significantly higher than its average of $19.93. The company reported strong quarterly earnings, exceeding analyst expectations with an adjusted EPS of $0.56 and revenue of $2.96 billion. Despite positive financial performance and analyst price target increases, the stock maintains a consensus "Reduce" rating with an average target of $22.45, while institutional investors hold a substantial 90.2% of outstanding shares.
